FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2293640430> ?p ?o ?g. }

• W2293640430 endingPage "20092" @default.
• W2293640430 startingPage "20080" @default.
• W2293640430 abstract "Sphingosine kinase 2 (Sphk2) has an oncogenic role in cancer. A recently developed first-in-class Sphk2 specific inhibitor ABC294640 displays antitumor activity in many cancer models. However, the role of Sphk2 and the antitumor activity of its inhibitor ABC294640 are not known in cholangiocarcinoma. We investigated the potential of targeting Sphk2 for the treatment of cholangiocarcinoma. We found that Sphk2 is overexpressed in five established human cholangiocarcinoma cell lines (WITT, HuCCT1, EGI-1, OZ and HuH28) and a new patient-derived cholangiocarcinoma cell line (LIV27) compared to H69 normal cholangiocytes. Inhibition of Sphk2 by ABC294640 inhibited proliferation and induced caspase-dependent apoptosis. Furthermore, we found that ABC294640 inhibited STAT3 phosphorylation, one of the key signaling pathways regulating cholangiocarcinoma cell proliferation and survival. ABC294640 also induced autophagy. Inhibition of autophagy by bafilomycin A1 or chloroquine potentiated ABC294640-induced cytotoxicity and apoptosis. In addition, ABC294640 in combination with sorafenib synergistically inhibited cell proliferation of cholangiocarcinoma cells. Strong decreases in STAT3 phosphorylation were observed in WITT and HuCCT1 cells exposed to the ABC294640 and sorafenib combination. These findings provide novel evidence that Sphk2 may be a rational therapeutic target in cholangiocarcinoma. Combinations of ABC294640 with sorafenib and/or autophagy inhibitors may provide novel strategies for the treatment of cholangiocarcinoma." @default.
• W2293640430 created "2016-06-24" @default.
• W2293640430 creator A5003169639 @default.
• W2293640430 creator A5008478890 @default.
• W2293640430 creator A5024051594 @default.
• W2293640430 creator A5027664400 @default.
• W2293640430 creator A5032606397 @default.
• W2293640430 creator A5032760861 @default.
• W2293640430 creator A5038949267 @default.
• W2293640430 creator A5042449797 @default.
• W2293640430 creator A5044769376 @default.
• W2293640430 creator A5045067652 @default.
• W2293640430 creator A5057408720 @default.
• W2293640430 creator A5060002817 @default.
• W2293640430 creator A5069073626 @default.
• W2293640430 creator A5084343942 @default.
• W2293640430 creator A5084427458 @default.
• W2293640430 date "2016-03-04" @default.
• W2293640430 modified "2023-10-02" @default.
• W2293640430 title "Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells" @default.
• W2293640430 cites W1511439086 @default.
• W2293640430 cites W1787950285 @default.
• W2293640430 cites W1855838686 @default.
• W2293640430 cites W1967966438 @default.
• W2293640430 cites W1972489536 @default.
• W2293640430 cites W1976756567 @default.
• W2293640430 cites W1996784003 @default.
• W2293640430 cites W2005990567 @default.
• W2293640430 cites W2006428522 @default.
• W2293640430 cites W2007242949 @default.
• W2293640430 cites W2009550277 @default.
• W2293640430 cites W2028700227 @default.
• W2293640430 cites W2039461396 @default.
• W2293640430 cites W2044724701 @default.
• W2293640430 cites W2046116275 @default.
• W2293640430 cites W2049383810 @default.
• W2293640430 cites W2052788204 @default.
• W2293640430 cites W2058525314 @default.
• W2293640430 cites W2062374027 @default.
• W2293640430 cites W2068228419 @default.
• W2293640430 cites W2073360856 @default.
• W2293640430 cites W2074284399 @default.
• W2293640430 cites W2078842981 @default.
• W2293640430 cites W2096439168 @default.
• W2293640430 cites W2097858421 @default.
• W2293640430 cites W2109827751 @default.
• W2293640430 cites W2110388058 @default.
• W2293640430 cites W2112257323 @default.
• W2293640430 cites W2114645683 @default.
• W2293640430 cites W2115236595 @default.
• W2293640430 cites W2120675908 @default.
• W2293640430 cites W2125732925 @default.
• W2293640430 cites W2132730335 @default.
• W2293640430 cites W2136466723 @default.
• W2293640430 cites W2137208895 @default.
• W2293640430 cites W2142845200 @default.
• W2293640430 cites W2145876349 @default.
• W2293640430 cites W2151217876 @default.
• W2293640430 cites W2154770245 @default.
• W2293640430 cites W2159740748 @default.
• W2293640430 cites W2163885294 @default.
• W2293640430 cites W2168493472 @default.
• W2293640430 doi "https://doi.org/10.18632/oncotarget.7914" @default.
• W2293640430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4991440" @default.
• W2293640430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26956050" @default.
• W2293640430 hasPublicationYear "2016" @default.
• W2293640430 type Work @default.
• W2293640430 sameAs 2293640430 @default.
• W2293640430 citedByCount "40" @default.
• W2293640430 countsByYear W22936404302016 @default.
• W2293640430 countsByYear W22936404302017 @default.
• W2293640430 countsByYear W22936404302018 @default.
• W2293640430 countsByYear W22936404302019 @default.
• W2293640430 countsByYear W22936404302020 @default.
• W2293640430 countsByYear W22936404302021 @default.
• W2293640430 countsByYear W22936404302022 @default.
• W2293640430 countsByYear W22936404302023 @default.
• W2293640430 crossrefType "journal-article" @default.
• W2293640430 hasAuthorship W2293640430A5003169639 @default.
• W2293640430 hasAuthorship W2293640430A5008478890 @default.
• W2293640430 hasAuthorship W2293640430A5024051594 @default.
• W2293640430 hasAuthorship W2293640430A5027664400 @default.
• W2293640430 hasAuthorship W2293640430A5032606397 @default.
• W2293640430 hasAuthorship W2293640430A5032760861 @default.
• W2293640430 hasAuthorship W2293640430A5038949267 @default.
• W2293640430 hasAuthorship W2293640430A5042449797 @default.
• W2293640430 hasAuthorship W2293640430A5044769376 @default.
• W2293640430 hasAuthorship W2293640430A5045067652 @default.
• W2293640430 hasAuthorship W2293640430A5057408720 @default.
• W2293640430 hasAuthorship W2293640430A5060002817 @default.
• W2293640430 hasAuthorship W2293640430A5069073626 @default.
• W2293640430 hasAuthorship W2293640430A5084343942 @default.
• W2293640430 hasAuthorship W2293640430A5084427458 @default.
• W2293640430 hasBestOaLocation W22936404301 @default.
• W2293640430 hasConcept C170493617 @default.
• W2293640430 hasConcept C184235292 @default.
• W2293640430 hasConcept C190283241 @default.
• W2293640430 hasConcept C203522944 @default.

• next